新华医疗(600587) - 2020 Q3 - 季度财报
SHINVASHINVA(SH:600587)2020-10-30 16:00

Financial Performance - Operating income for the first nine months was approximately ¥6.53 billion, representing a year-on-year increase of 3.43%[16]. - Net profit attributable to shareholders of the listed company decreased by 73.45% to approximately ¥213 million[16]. - Basic earnings per share decreased by 73.60% to ¥0.52[16]. - The weighted average return on equity decreased by 16.68 percentage points to 4.97%[16]. - The company reported a significant increase of 696.94% in net profit attributable to shareholders after deducting non-recurring gains and losses, reaching approximately ¥187 million[16]. - The company's net profit for the first three quarters of 2020 showed a significant change compared to the same period last year, primarily due to the sale of equity stakes in subsidiaries, with a growth of approximately 175.22% when excluding these factors[25]. - Net profit for the first three quarters of 2020 was ¥860,976,048.66, compared to ¥681,097,636.38 in the same period of 2019, representing a growth of approximately 26.4%[34]. - The company reported a total comprehensive income for Q3 2020 of CNY 82.65 million, compared to CNY 105.98 million in Q3 2019, showing a decrease of about 22.0%[38]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥11.59 billion, a decrease of 0.15% compared to the end of the previous year[16]. - The company's total assets stood at CNY 11.59 billion, slightly down from CNY 11.61 billion, showing a decrease of about 0.1%[31]. - Total liabilities decreased to approximately CNY 6.75 billion from CNY 6.92 billion, a reduction of about 2.4%[31]. - The total amount of contract liabilities reached ¥1,385,768,365.50, reflecting a 100% increase due to the implementation of new revenue recognition standards[22]. - The company's long-term payables decreased by 36.89% to ¥2,143,932.52, attributed to a reduction in goods procured through financing leases[22]. - The accounts payable increased by 29.63% to ¥308,351,546.19, primarily due to an increase in accepted bills issued during the period[22]. - The total liabilities were recorded at 6,915,055,643.37 RMB, indicating a stable financial position[52]. Cash Flow - Net cash flow from operating activities increased by 43.40% to approximately ¥634 million for the first nine months[16]. - Cash inflow from operating activities totaled CNY 7,890,161,944.15, up from CNY 7,219,002,934.94 in the previous year, marking an increase of approximately 9.3%[44]. - Cash outflow from operating activities was CNY 7,256,243,787.40, compared to CNY 6,776,930,151.54 in 2019, reflecting an increase of about 7.1%[44]. - The net cash flow from investment activities was negative at CNY -11,237,096.35, an improvement from CNY -306,774,747.17 in the same period of 2019[45]. - The company reported a net increase in cash and cash equivalents of CNY 35,831,838.33 for the first three quarters of 2020, contrasting with a decrease of CNY 221,940,327.49 in the same period of 2019[45]. Shareholder Information - Net assets attributable to shareholders of the listed company increased by 4.38% to approximately ¥4.36 billion[16]. - The total number of shareholders at the end of the reporting period was 33,974[18]. - The company's total equity increased to ¥3,092,775,042.48 from ¥2,911,961,582.38, representing a growth of approximately 6.2%[34]. Inventory and Receivables - Inventory increased to CNY 2.34 billion from CNY 2.15 billion, reflecting a rise of about 8.6%[30]. - The company's accounts receivable for commercial acceptance bills decreased to zero, reflecting a 100% reduction as they matured[22]. - Accounts receivable increased to ¥675,609,933.48 from ¥645,916,380.27, showing a rise of about 4.0%[33]. - The company reported a significant amount of accounts receivable totaling RMB 645,916,380.27, indicating strong customer demand[54]. Tax and Expenses - The company's income tax expense decreased by 60.07% to ¥80,333,609.44, primarily due to tax expenses related to the transfer of equity stakes in subsidiaries[22]. - Research and development expenses for Q3 2020 were ¥52,053,251.22, compared to ¥53,227,727.27 in Q3 2019, indicating a slight decrease of about 2.2%[35]. - The income tax expense for Q3 2020 was CNY 7.10 million, compared to CNY 0.69 million in Q3 2019, indicating a significant increase[41].

SHINVA-新华医疗(600587) - 2020 Q3 - 季度财报 - Reportify